TCR Vβ (T-cell receptor variable beta) Inhibitors represent a class of chemical compounds that are primarily designed to modulate the function and activity of specific T-cell receptors (TCRs). T-cell receptors play a pivotal role in the adaptive immune system, as they are responsible for recognizing and binding to antigens presented by antigen-presenting cells, thereby initiating an immune response. The TCR Vβ subtype is a specific subset of T-cell receptors that contribute to antigen recognition and immune activation. TCR Vβ Inhibitors are engineered to selectively target and inhibit the function of these particular TCRs, often by interfering with their binding affinity to antigens or by disrupting downstream signaling pathways.
These inhibitors are of significant interest in the field of immunology and research related to autoimmune diseases and immune-related disorders. By modulating the activity of TCR Vβ, researchers aim to gain a better understanding of the mechanisms underlying immune responses and, in particular, how aberrant T-cell activation may contribute to autoimmune conditions. TCR Vβ Inhibitors can be valuable tools for elucidating these processes and may offer insights into the development of strategies to regulate or control T-cell responses in various pathological contexts. They also serve as critical research reagents for investigating the fundamental aspects of immunology and T-cell biology.
SEE ALSO...
Items 11 to 12 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor, and while it primarily targets BCR-ABL, it could potentially affect various pathways in T cells, including TCR V β expression. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $49.00 $367.00 $2030.00 | 18 | |
Lenalidomide affects various signaling pathways and has immunomodulatory effects, potentially leading to altered TCR V β expression. |